Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2019-08-01

FDA Approved: DIHYDROERGOTAMINE MESYLATE — Supplemental Application (Oceanside Pharmaceuticals)

View source ↗

Summary

FDA approved Oceanside Pharmaceuticals' supplemental application for Dihydroergotamine mesylate, updating the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dihydroergotamine mesylate (Dihydroergotamine Mesylate)

Snippet

SUPPL AP for DIHYDROERGOTAMINE MESYLATE (DIHYDROERGOTAMINE MESYLATE)